title: Dual effect of tamoxifen on arterial KCa channels does not depend on the presence of the beta1 subunit.
abstract: Tamoxifen has been reported to directly activate large conductance calcium-activated potassium (KCa) channels through the KCa beta1 subunit, suggesting a cardio-protective role of this compound. The present study using knock-out (KO) mice for the KCa channel beta1 subunit was aimed at understanding the molecular mechanisms of the effects of tamoxifen on arterial smooth muscle KCa channels. Single channel studies were conducted in excised patches from cerebral artery myocytes from both wild-type and KO animals. The present data demonstrated that tamoxifen can inhibit arterial KCa channels due to a major decrease in channel open probability (P(o)), a mechanism different from the reduction in single channel amplitude reported previously and also observed in the present work. A tamoxifen-induced decrease in P(o) was present in arterial KCa channels from both wild-type and beta1 KO animals. This inhibition was concentration-dependent and partially reversible with a half-maximal concentration constant IC(50) of 2.6 microm. The effect of tamoxifen was actually dual Single channel kinetic analysis showed that tamoxifen shortens both mean closed time and mean open time; the latter is probably due to an intermediate duration voltage-independent blocking mechanism. Thus, tamoxifen block would predominate when KCa channel P(o) is >0.1-0.2, limiting the maximum P(o), whereas a leftward shift in voltage or Ca(2+) activation curves can be observed for P(o) values lower than those values. This dual effect of tamoxifen appears to be independent of the beta1 subunit. The molecular specificity of tamoxifen, or eventually other xenoestrogen derivatives, for the KCa channel beta1 subunit is uncertain.
authors.affiliation: Masonic Medical Research Laboratory, Utica, NY 13501, USA. gperez@mmrl.edu
authors.forename: Guillermo J
authors.initials: GJ
authors.lastname: Pérez
mesh_terms: D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology; D001158:Arteries / Q000378:metabolism; D001665:Binding Sites; D002118:Calcium / Q000378:metabolism; D002462:Cell Membrane / Q000378:metabolism; D002536:Cerebral Arteries / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004967:Estrogens / Q000737:chemistry; D005260:Female; D005838:Genotype; D020128:Inhibitory Concentration 50; D007700:Kinetics; D016014:Linear Models; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009130:Muscle, Smooth / Q000166:cytology; D032389:Myocytes, Smooth Muscle / Q000166:cytology; D016133:Polymerase Chain Reaction; D015221:Potassium Channels / Q000737:chemistry* / Q000378:metabolism; D011485:Protein Binding; D017434:Protein Structure, Tertiary; D012984:Software; D013629:Tamoxifen / Q000494:pharmacology*; D013997:Time Factors
chemical_list: D018931:Antineoplastic Agents, Hormonal; D004967:Estrogens; D015221:Potassium Channels; D013629:Tamoxifen; D002118:Calcium